Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel or cabazitaxel with or without darolutamide in metastatic castration-resistant prostate cancer
2022-003792-41Phase 2Active
- Sponsor
- Erasmus MC
- Start
- Jan 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of darolutamide in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Erasmus MC. Primary endpoint: Progression-free survival. Started Jan 2023; status: active.
02
Drugs
darolutamide
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2022-003792-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-003792-41.